Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Impact · against what's priced in

The outlook for Moderna is negative as analysts forecast a significant revenue decline and deepening annual losses. Despite recent short-term price momentum, the fundamental expectations for upcoming earnings suggest systemic headwinds for the stock.

MRNA−0.30

No priced-in read yet

In context

Expected quarterly revenue of $114.89 million represents a 19.09% year-over-year decrease, while full-year earnings are predicted to drop 14.74% to -$8.33 per share.

Read from the article alone

• MRNA▲150%
• equity research▲30%
• earnings▲<1%
• healthcare
• biotechnology
• revenue forecast